A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Zhu, Y.J.; Zheng, B.; Wang, H.Y.; Chen, L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol. Sin. 2017, 38, 614–622. [Google Scholar] [CrossRef] [PubMed]
- Keating, G.M. Sorafenib: A Review in Hepatocellular Carcinoma. Target. Oncol. 2017, 12, 243–253. [Google Scholar] [CrossRef] [PubMed]
- Adnane, L.; Trail, P.A.; Taylor, I.; Wilhelm, S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407, 597–612. [Google Scholar] [CrossRef] [PubMed]
- Moldogazieva, N.T.; Zavadskiy, S.P.; Sologova, S.S.; Mokhosoev, I.M.; Terentiev, A.A. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert. Rev. Mol. Diagn. 2021, 21, 1147–1164. [Google Scholar] [CrossRef] [PubMed]
- Benson, A.B., III; D’Angelica, M.I.; Abbott, D.E. NCCN guidelines insights hepatobiliary cancers version 2. J. Natl. Compr. Cancer Netw. 2019, 17, 302–310. [Google Scholar] [CrossRef]
- Zhang, X.-H.; Cao, M.-Q.; Li, X.X.; Zhang, T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J. Hepatol. 2020, 12, 766–774. [Google Scholar] [CrossRef]
- Zhao, Y.; Zhang, Y.-N.; Wang, K.-T.; Chen, L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim. Biophys. Acta BBA Rev. Cancer 2020, 1874, 188391. [Google Scholar] [CrossRef] [PubMed]
- Kong, Y.; Sun, L.; Hou, Z. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget 2017, 8, 105596–105605. [Google Scholar] [CrossRef] [PubMed]
- Yu, W.-C.; Zhang, K.-Z.; Chen, S.-G.; Liu, W.-F. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. Medicine 2018, 97, e9704. [Google Scholar] [CrossRef]
- Zhen, L.; Jiali, C.; Yong, F.; Han, X.; Hongming, P.; Weidong, H. The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: A retrospective study. J. Cancer 2018, 9, 2773–2777. [Google Scholar] [CrossRef]
- Zhang, Y.; Fan, W.; Wang, Y.; Huang, G.; Li, J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control 2019, 26, 1073274819872216. [Google Scholar] [CrossRef]
- Du, X.; Chen, D.; Lin, Z. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: A retrospective, multicenter study. JBUON 2019, 24, 1956–1963. [Google Scholar]
- Xing, R.; Gao, J.; Cui, Q.; Wang, Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front. Immunol. 2021, 12, 783236. [Google Scholar] [CrossRef] [PubMed]
- Butte, M.J.; Keir, M.E.; Phamduy, T.B.; Sharpe, A.H.; Freeman, G.J. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity 2007, 27, 111–122. [Google Scholar] [CrossRef]
- Hegde, P.S.; Wallin, J.J.; Mancao, C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 2018, 52, 117–124. [Google Scholar] [CrossRef] [PubMed]
- Ma, J.; Chen, X.-Q.; Xiang, Z.-L.; Isaguliants, M. Identification of a Prognostic Transcriptome Signature for Hepatocellular Carcinoma with Lymph Node Metastasis. Oxidative Med. Cell. Longev. 2022, 2022, 7291406. [Google Scholar] [CrossRef] [PubMed]
- Galle, P.R.; Foerster, F.; Kudo, M.; Chan, S.L.; Llovet, J.M.; Qin, S.; Schelman, W.R.; Chintharlapalli, S.; Abada, P.B.; Sherman, M.; et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019, 39, 2214–2229. [Google Scholar] [CrossRef] [PubMed]
- Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25–34. [Google Scholar] [CrossRef] [PubMed]
- Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018, 391, 1163–1173. [Google Scholar] [CrossRef] [PubMed]
- Bykov, V.J.N.; Eriksson, S.E.; Bianchi, J.; Wiman, K.G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 2018, 18, 89–102. [Google Scholar] [CrossRef]
- Liang, Y.; Jiang, L.; Zhong, X.; Hochwald, S.N.; Wang, Y.; Huang, L.; Nie, Q.; Huang, H.; Xu, J.F. Discovery of Aberrant Alteration of Genome in Colorectal Cancer by Exome Sequencing. Am. J. Med. Sci. 2019, 358, 340–349. [Google Scholar] [CrossRef] [PubMed]
- Duan, M.; Hao, J.; Cui, S.; Worthley, D.L.; Zhang, S.; Wang, Z.; Shi, J.; Liu, L.; Wang, X.; Ke, A.; et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018, 28, 359–373. [Google Scholar] [CrossRef]
- Qiu, L.; Wu, J.; Pan, C.; Tan, X.; Lin, J.; Liu, R.; Chen, S.; Geng, R.; Huang, W. Downregulation of CDC27 inhibits the proliferation of colorectal cancer cells via the accumulation of p21Cip1/Waf1. Cell Death Dis. 2016, 7, e2074. [Google Scholar] [CrossRef] [PubMed]
- Qiu, L.; Tan, X.; Lin, J.; Liu, R.Y.; Chen, S.; Geng, R.; Wu, J.; Huang, W. CDC27 Induces Metastasis and Invasion in Colorectal Cancer via the Promotion of Epithelial-To-Mesenchymal Transition. J. Cancer 2017, 8, 2626–2635. [Google Scholar] [CrossRef] [PubMed]
- Baek, B.; Lee, H. Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data. Sci. Rep. 2020, 10, 18951. [Google Scholar] [CrossRef] [PubMed]
- Khalilipour, N.; Baranova, A.; Jebelli, A.; Heravi-Moussavi, A.; Bruskin, S.; Abbaszadegan, M.R. Familial Esophageal Squamous Cell Carcinoma with damaging rare/germline mutations in KCNJ12/KCNJ18 and GPRIN2 genes. Cancer Genet. 2018, 221, 46–52. [Google Scholar] [CrossRef]
- Zhu, L.J. trackViewer: A Bioconductor package for interactive and integrative visualization of multi-omics data. Nat. Methods 2019, 16, 453–454. [Google Scholar]
- Li, C.; Han, J.; Yao, Q.; Zou, C.; Xu, Y.; Zhang, C.; Shang, D.; Zhou, L.; Zou, C.; Sun, Z.; et al. Subpathway-GM: Identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucleic Acids Res. 2013, 41, e101. [Google Scholar] [CrossRef] [PubMed]
- Colaprico, A.; Silva, T.C.; Olsen, C.; Garofano, L.; Cava, C.; Garolini, D.; Sabedot, T.S.; Malta, T.M.; Pagnotta, S.M.; Castiglioni, I.; et al. TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016, 44, e71. [Google Scholar] [CrossRef] [PubMed]
- Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhim, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011, 12, R41. [Google Scholar] [CrossRef]
- Mayakonda, A.; Lin, D.C.; Assenov, Y.; Plass, C.; Koeffler, H.P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018, 28, 1747–1756. [Google Scholar] [CrossRef] [PubMed]
- Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef]
- Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012, 16, 284–287. [Google Scholar] [CrossRef] [PubMed]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [PubMed]
- Xiao, Y.; Ma, D.; Zhao, S.; Suo, C.; Shi, J.; Xue, M.Z.; Ruan, M.; Wang, H.; Zhao, J.; Li, Q.; et al. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin. Cancer Res. 2019, 25, 5002–5014. [Google Scholar] [CrossRef] [PubMed]
- Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [PubMed]
- Herranz Amo, F.; Rivero Sánchez, E.; Verdú Tartajo, F.; Hernández Fernández, C.; Díez Cordero, J.M. [Cysts of the seminal vesicles: Apropos of a case]. Actas Urol. Esp. 1987, 11, 210–213. [Google Scholar] [PubMed]
Before Treatment | ||||
Pathway Name | p Value | Fdr | Gene Name | Gene Status |
MAPK signaling pathway | 0.006894022 | 1 | FLNB/TP53/HSPA6MAP2K3 | activation |
PI3K-Akt signaling pathway | 0.008034318 | 1 | COL24A1/COL6A6/COL4A3/COL6A2 | inhibition |
Apoptosis | 0.033360695 | 1 | ATM/BCL2/TP53 | inhibition |
Hepatitis B | 0.044232577 | 1 | CDK2/CDKN1B/CDKN1A/TP53 | activation |
After Treatment | ||||
Pathway Name | p Value | Fdr | Gene Name | Gene Status |
MAPK signaling pathway | 0.003797448 | 0.318171929 | BRAF/RAP1B/MAPK3/NF1/MAP3K1/HRAS/RASA2/ | inhibition |
PI3K-Akt signaling pathway | 0.019029251 | 0.598612574 | PTEN/CRTC2/CDC37/MLST8/ATF6B/RHEB/RPS6/PPP2R1A | activation |
Apoptosis | 0.045364706 | 0.476518519 | ACTG1/ATM/BIRC5/DAXX/FOS/GADD45B/HRAS/IL3RA/LMNA/MAPK3/PIDD1/PIK3CA/RELA/TRADD/TUBA3C | activation |
Hepatitis B | 0.047111607 | 0.774766417 | MAPK3/ATF6B/RELA/FOS | inhibition |
PD-L1 expression and PD-1 checkpoint pathway in cancer | 0.040184742 | 0.476518519 | CSNK2A3/FOS/HRAS/MAPK3/MYD88/NFKBIB/PIK3CA/PTEN/RELA/TICAM2/TRAF6 | activation |
NF-kappa B signaling pathway | 0.01547192 | 0.541748109 | TRAF6/TICAM2/MYD88/TRADD | inhibition |
T cell receptor signaling pathway | 0.039225403 | 0.701472906 | MAPK3/FOS/HRAS | activation |
p53 signaling pathway | 0.010435202 | 0.200648803 | ATM/ATR/CCNB1/CCNB2/CDK1/GADD45B/GTSE1/PIDD1/PTEN/SFN/SHISA5 | activation |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, J.; Liang, R.; Lu, C.; Lu, L.; Li, S.; Tang, M.; Huang, X.; Huang, S.; Mai, R.; Gao, X.; et al. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma. Int. J. Mol. Sci. 2023, 24, 13486. https://doi.org/10.3390/ijms241713486
Huang J, Liang R, Lu C, Lu L, Li S, Tang M, Huang X, Huang S, Mai R, Gao X, et al. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023; 24(17):13486. https://doi.org/10.3390/ijms241713486
Chicago/Turabian StyleHuang, Julu, Rong Liang, Cheng Lu, Lu Lu, Shuanghang Li, Minchao Tang, Xi Huang, Shilin Huang, Rongyun Mai, Xing Gao, and et al. 2023. "A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma" International Journal of Molecular Sciences 24, no. 17: 13486. https://doi.org/10.3390/ijms241713486